References
- “Chronic obstructive pulmonary disease (COPD).” Accessed: Mar. 02, 2025. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
- E. T. 3 min read, “Smoking & COPD,” COPD.net. Accessed: Mar. 02, 2025. [Online]. Available: https://copd.net/basics/causes-risk-factors/smoking
- Q. Song, P. Chen, and X.-M. Liu, “The role of cigarette smoke-induced pulmonary vascular endothelial cell apoptosis in COPD,” Respir. Res., vol. 22, no. 1, p. 39, Feb. 2021, doi: 10.1186/s12931-021-01630-1.
- J. A. Riesco, B. Alcázar, J. A. Trigueros, A. Campuzano, J. Perez, and J. L. Lorenzo, “Active smoking and COPD phenotype: distribution and impact on prognostic factors,” Int. J. Chron. Obstruct. Pulmon. Dis., vol. 12, pp. 1989–1999, 2017, doi: 10.2147/COPD.S135344.
- A. Fazleen and T. Wilkinson, “Early COPD: current evidence for diagnosis and management,” Ther. Adv. Respir. Dis., vol. 14, p. 1753466620942128, 2020, doi: 10.1177/1753466620942128.
- “WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke.” Accessed: Jan. 20, 2025. [Online]. Available: https://www.who.int/publications/i/item/9789240077164
- M. I. Saeed et al., “TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol-a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of ‘high-intensity’ vs. ‘low-intensity’ smoking cessation intervention in active smokers with chronic obstructive pulmonary disease,” Trials, vol. 21, no. 1, p. 730, Aug. 2020, doi: 10.1186/s13063-020-04653-z.
- D. Campagna et al., “Smoking and diabetes: dangerous liaisons and confusing relationships,” Diabetol. Metab. Syndr., vol. 11, p. 85, 2019, doi: 10.1186/s13098-019-0482-2.
- K. Larsson, “Aspects on pathophysiological mechanisms in COPD,” J. Intern. Med., vol. 262, no. 3, pp. 311–340, Sep. 2007, doi: 10.1111/j.1365-2796.2007.01837.x.
- J. C. S. Holtjer et al., “Identifying risk factors for COPD and adult-onset asthma: an umbrella review,” Eur. Respir. Rev. Off. J. Eur. Respir. Soc., vol. 32, no. 168, p. 230009, Jun. 2023, doi: 10.1183/16000617.0009-2023.
- M. Shnaigat, S. Downie, and H. Hosseinzadeh, “Effectiveness of Health Literacy Interventions on COPD Self-Management Outcomes in Outpatient Settings: A Systematic Review,” COPD, vol. 18, no. 3, pp. 367–373, Jun. 2021, doi: 10.1080/15412555.2021.1872061.
- N. A. Rigotti, “Smoking cessation in patients with respiratory disease: existing treatments and future directions,” Lancet Respir. Med., vol. 1, no. 3, pp. 241–250, May 2013, doi: 10.1016/S2213-2600(13)70063-8.
- V. Austin, P. J. Crack, S. Bozinovski, A. A. Miller, and R. Vlahos, “COPD and stroke: are systemic inflammation and oxidative stress the missing links?,” Clin. Sci. Lond. Engl. 1979, vol. 130, no. 13, pp. 1039–1050, Jul. 2016, doi: 10.1042/CS20160043.
- S. Dey, M. S. Eapen, C. Chia, A. V. Gaikwad, P. A. B. Wark, and S. S. Sohal, “Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities,” Am. J. Physiol. Lung Cell. Mol. Physiol., vol. 322, no. 1, pp. L64–L83, Jan. 2022, doi: 10.1152/ajplung.00121.2021.
- N. L. Benowitz, J. Samet, N. Soleimanpour, and B. W. Chaffee, “Biomarkers of improved health outcomes after smoking cessation,” Addict. Neurosci., vol. 5, p. 100054, Mar. 2023, doi: 10.1016/j.addicn.2022.100054.
- K. H. Czarnecka-Chrebelska, D. Mukherjee, S. V. Maryanchik, and M. Rudzinska-Radecka, “Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer,” Biomedicines, vol. 11, no. 2, p. 448, Feb. 2023, doi: 10.3390/biomedicines 11020448.
- Y.Wang, J. Xu, Y. Meng, I. M. Adcock, and X. Yao, “Role of inflammatory cells in airway remodeling in COPD,” Int. J. Chron. Obstruct. Pulmon. Dis., vol. 13, pp. 3341–3348, 2018, doi: 10.2147/COPD.S176122.
- A. J. A. McGuinness and E. Sapey, “Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms,” J. Clin. Med., vol. 6, no. 2, p. 21, Feb. 2017, doi: 10.3390/jcm6020021.
- M. Hikichi, K. Mizumura, S. Maruoka, and Y. Gon, “Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke,” J. Thorac. Dis., vol. 11, no. Suppl 17, pp. S2129–S2140, Oct. 2019, doi: 10.21037/jtd.2019.10.43.
- P. J. Barnes, S. D. Shapiro, and R. A. Pauwels, “Chronic obstructive pulmonary disease: molecular and cellular mechanisms,” Eur. Respir. J., vol. 22, no. 4, pp. 672–688, Oct. 2003, doi: 10.1183/09031936.03.00040703.
- H. G. Dailah, “Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review,” Mol. Basel Switz., vol. 27, no. 17, p. 5542, Aug. 2022, doi: 10.3390/molecules27175542.
- X. Zhao, Q. Zhang, and R. Zheng, “The interplay between oxidative stress and autophagy in chronic obstructive pulmonary disease,” Front. Physiol., vol. 13, p. 1004275, 2022, doi: 10.3389/fphys.2022.1004275.
- B. M. Fischer, E. Pavlisko, and J. A. Voynow, “Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation,” Int. J. Chron. Obstruct. Pulmon. Dis., vol. 6, pp. 413–421, 2011, doi: 10.2147/COPD.S10770.
- S. Safiri et al., “Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019,” BMJ, vol. 378, p. e069679, Jul. 2022, doi: 10.1136/bmj-2021-069679.
- S. Kotlyarov, “The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis,” Int. J. Mol. Sci., vol. 24, no. 10, p. 8725, May 2023, doi: 10.3390/ijms24108725.
- D. H. Au et al., “The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations,” J. Gen. Intern. Med., vol. 24, no. 4, pp. 457–463, Apr. 2009, doi: 10.1007/s11606-009-0907-y.
- J. R. Hurst et al., “Susceptibility to exacerbation in chronic obstructive pulmonary disease,” N. Engl. J. Med., vol. 363, no. 12, pp. 1128–1138, Sep. 2010, doi: 10.1056/NEJMoa0909883.
- A. Domenech et al., “High risk of subclinical atherosclerosis in COPD exacerbator phenotype,” Respir. Med., vol. 141, pp. 165–171, Aug. 2018, doi: 10.1016/j.rmed.2018.07.004.
- A. Forder et al., “Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer,” Int. J. Mol. Sci., vol. 24, no. 3, p. 2859, Feb. 2023, doi: 10.3390/ijms24032859.
- M. Underner, J. Perriot, and G. Peiffer, “[Smoking cessation in smokers with chronic obstructive pulmonary disease],” Rev. Mal. Respir., vol. 31, no. 10, pp. 937–960, Dec. 2014, doi: 10.1016/j.rmr.2014.07.001.
- P. Tønnesen, K. Mikkelsen, and L. Bremann, “Nurseconducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support,” Chest, vol. 130, no. 2, pp. 334–342, Aug. 2006, doi: 10.1378/chest.130.2.334.
- B.W. M. Willemse, D. S. Postma, W. Timens, and N. H. T. ten Hacken, “The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation,” Eur. Respir. J., vol. 23, no. 3, pp. 464–476, Mar. 2004, doi: 10.1183/09031936.04.00012704.
- Y. Liu et al., “Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history,” Int. J. Chron. Obstruct. Pulmon. Dis., vol. 10, pp. 1409–1416, 2015, doi: 10.2147/COPD.S82259.
- Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), and Office on Smoking and Health (US), How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. in Publications and Reports of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US), 2010. Accessed: Jan. 20, 2025. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK53017/
- A. Pezzuto, C. Spoto, B. Vincenzi, and G. Tonini, “Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level,” J. Comp. Eff. Res., vol. 2, no. 3, pp. 335–343, May 2013, doi: 10.2217/cer.13.25.
- E. Maci, F. Comito, A. M. Frezza, G. Tonini, and A. Pezzuto, “Lung nodule and functional changes in smokers after smoking cessation short-term treatment,” Cancer Invest., vol. 32, no. 8, pp. 388–393, Oct. 2014, doi: 10.3109/07357907.2014.919308.
- M. Iwaoka and T. Tsuji, “Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age,” Intern. Med. Tokyo Jpn., vol. 55, no. 17, pp. 2387–2392, 2016, doi: 10.2169/internalmedicine.55.6844.
- P. D. Scanlon et al., “Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study,” Am. J. Respir. Crit. Care Med., vol. 161, no. 2 Pt 1, pp. 381–390, Feb. 2000, doi: 10.1164/ajrccm.161.2.9901044.
- J. Dhariwal et al., “Smoking cessation in COPD causes a transient improvement in spirometry and decreases micronodules on high-resolution CT imaging,” Chest, vol. 145, no. 5, pp. 1006–1015, May 2014, doi: 10.1378/chest.13-2220.
- P. N. Lee and J. S. Fry, “Systematic review of the evidence relating FEV1 decline to giving up smoking,” BMC Med., vol. 8, p. 84, Dec. 2010, doi: 10.1186/1741-7015-8-84.
- D. P. Tashkin, S. Rennard, J. Taylor Hays, D. Lawrence, J. P. Marton, and T. C. Lee, “Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients,” Respir.Med., vol. 105, no. 11, pp. 1682–1690, Nov. 2011, doi: 10.1016/j.rmed.2011.04.016.
- J. Vestbo et al., “Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team,” Am. J. Respir. Crit. Care Med., vol. 189, no. 9, pp. 1022–1030, May 2014, doi: 10.1164/rccm.201311-2006PP.
- P. Tønnesen, “Smoking cessation and COPD,” Eur. Respir. Rev. Off. J. Eur. Respir. Soc., vol. 22, no. 127, pp. 37–43, Mar. 2013, doi: 10.1183/09059180.00007212.
- O. Hatayama, T. Kobayashi, K. Fujimoto, and K. Kubo, “Utility of single-slice high-resolution CT in upper lung field combined with low-dose spiral CT for lung-cancer screening in the detection of emphysema,” Intern. Med. Tokyo Jpn., vol. 46, no. 18, pp. 1519–1525, 2007, doi: 10.2169/internalmedicine.46.6343.
- H. Omori, K. Fujimoto, and T. Katoh, “Computed-tomography findings of emphysema: correlation with spirometric values,” Curr. Opin. Pulm. Med., vol. 14, no. 2, pp. 110–114, Mar. 2008, doi: 10.1097/MCP.0b013e3282f 3f18f.
- K. Kurashima et al., “High resolution CT and bronchial reversibility test for diagnosing COPD,” Respirol. Carlton Vic, vol. 10, no. 3, pp. 316–322, Jun. 2005, doi: 10.1111/j.1440-1843.2005.00701.x.
- F. A. A. Mohamed Hoesein et al., “CT-quantified emphysema in male heavy smokers: association with lung function decline,” Thorax, vol. 66, no. 9, pp. 782–787, Sep. 2011, doi: 10.1136/thx.2010.145995.
- J.-P. Charbonnier et al., “Airway wall thickening on CT: Relation to smoking status and severity of COPD,” Respir. Med., vol. 146, pp. 36–41, Jan. 2019, doi: 10.1016/j.med.2018.11.014.
- G. R. Washko et al., “Lung volumes and emphysema in smokers with interstitial lung abnormalities,” N. Engl. J. Med., vol. 364, no. 10, pp. 897–906, Mar. 2011, doi: 10.1056/NEJMoa1007285.
- M. Remy-Jardin, J.-L. Edme, C. Boulenguez, J. Remy, I. Mastora, and A. Sobaszek, “Longitudinal follow-up study of smoker’s lung with thin-section CT in correlation with pulmonary function tests,” Radiology, vol. 222, no. 1, pp. 261–270, Jan. 2002, doi: 10.1148/radiol.2221001154.
- J. E. McDonough et al., “Small-airway obstruction and emphysema in chronic obstructive pulmonary disease,” N. Engl. J. Med., vol. 365, no. 17, pp. 1567–1575, Oct. 2011, doi: 10.1056/NEJMoa1106955.
- S. A. Chang, “Smoking and type 2 diabetes mellitus,” Diabetes Metab. J., vol. 36, no. 6, pp. 399–403, Dec. 2012, doi: 10.4093/dmj.2012.36.6.399.
- J. A. Riesco, M. Hidalgo, D. Chipayo, J. J. Gómez, and F. Zaragozá, “Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit,” Adv. Ther., vol. 37, no. 8, pp. 3562–3570, Aug. 2020, doi: 10.1007/s12325-020-01403-0.
- S. M. Mohiuddin, A. N. Mooss, C. B. Hunter, T. L. Grollmes, D. A. Cloutier, and D. E. Hilleman, “Intensive smoking cessation intervention reduces mortality in highrisk smokers with cardiovascular disease,” Chest, vol. 131, no. 2, pp. 446–452, Feb. 2007, doi: 10.1378/chest.06-1587.
- P.W. F. Wilson, “Smoking, smoking cessation, and risk of cardiovascular disease,” Curr. Treat. Options Cardiovasc. Med., vol. 8, no. 4, pp. 276–281, Aug. 2006, doi: 10.1007/s11936-006-0048-0.
- N. S. Godtfredsen and E. Prescott, “Benefits of smoking cessation with focus on cardiovascular and respiratory comorbidities,” Clin. Respir. J., vol. 5, no. 4, pp. 187–194, Oct. 2011, doi: 10.1111/j.1752-699X.2011.00262.x.
- A. A. Ahmed et al., “Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking,” Circ. Heart Fail., vol. 8, no. 4, pp. 694–701, Jul. 2015, doi: 10.1161/CIRCHEARTFAILURE.114.001885.
- A. Bakhru and T. P. Erlinger, “Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey,” PLoS Med., vol. 2, no. 6, p. e160, Jun. 2005, doi: 10.1371/journal.pmed.0020160.
- C. Bullen, “Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease,” Expert Rev. Cardiovasc. Ther., vol. 6, no. 6, pp. 883–895, Jul. 2008, doi: 10.1586/14779072.6.6.883.
- A. L. Pipe, M. J. Eisenberg, A. Gupta, R. D. Reid, N. G. Suskin, and J. A. Stone, “Smoking cessation and the cardiovascular specialist: Canadian Cardiovascular Society position paper,” Can. J. Cardiol., vol. 27, no. 2, pp. 132–137, 2011, doi: 10.1016/j.cjca.2010.12.060.
- G. Gallucci, A. Tartarone, R. Lerose, A. V. Lalinga, and A. M. Capobianco, “Cardiovascular risk of smoking and benefits of smoking cessation,” J. Thorac. Dis., vol. 12, no. 7, pp. 3866–3876, Jul. 2020, doi: 10.21037/jtd.2020.02.47.
- D. Girard et al., “Long-term smoking cessation and heart rate dynamics in an aging healthy cohort: Is it possible to fully recover?,” Environ. Res., vol. 143, no. Pt A, pp. 39–48, Nov. 2015, doi: 10.1016/j.envres.2015.09.023.
- A. J. Dobson, H. M. Alexander, R. F. Heller, and D. M. Lloyd, “How soon after quitting smoking does risk of heart attack decline?,” J. Clin. Epidemiol., vol. 44, no. 11, pp. 1247–1253, 1991, doi: 10.1016/0895-4356(91)90157-5.
- K. K. Teo et al., “Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a casecontrol study,” Lancet Lond. Engl., vol. 368, no. 9536, pp. 647–658, 2006, doi: 10.1016/S0140-6736(06)69249-0.
- D. Twardella, D. Rothenbacher, H. Hahmann, B. Wusten, and H. Brenner, “The underestimated impact of smoking and smoking cessation on the risk of secondary cardiovascular disease events in patients with stable coronary heart disease: prospective cohort study,” J. Am. Coll. Cardiol., vol. 47, no. 4, pp. 887–889, Feb. 2006, doi: 10.1016/j.jacc.2005.11.028.
- A. P. Silva et al., “Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting,” BMC Cardiovasc. Disord., vol. 16, p. 2, Jan. 2016, doi: 10.1186/s12872-015-0180-4.
- B. P. Yawn and A. Kaplan, “Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation?,” Prim. Care Respir. J. J. Gen. Pract. Airw. Group, vol. 17, no. 4, pp. 199–205, Dec. 2008, doi: 10.3132/pcrj.2008.00021.
- E. Barreiro, V. Bustamante, V. Curull, J. Gea, J. L. López-Campos, and X. Muñoz, “Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights,” J. Thorac. Dis., vol. 8, no. 10, pp. E1122–E1135, Oct. 2016, doi: 10.21037/jtd.2016.09.54.
- D. Amicizia et al., “Systematic Review of Lung Cancer Screening: Advancements and Strategies for Implementation,” Healthc. Basel Switz., vol. 11, no. 14, p. 2085, Jul. 2023, doi: 10.3390/healthcare11142085.
- R. Uliński, I. Kwiecień, and J. Domagała-Kulawik, “Lung Cancer in the Course of COPD-Emerging Problems Today,” Cancers, vol. 14, no. 15, p. 3819, Aug. 2022, doi: 10.3390/cancers14153819.
- A. Cavaillès et al., “Comorbidities of COPD,” Eur. Respir. Rev. Off. J. Eur. Respir. Soc., vol. 22, no. 130, pp. 454–475, Dec. 2013, doi: 10.1183/09059180.00008612.
- R. P. Young and R. J. Hopkins, “How the genetics of lung cancermay overlap with COPD,” Respirol. Carlton Vic, vol. 16, no. 7, pp. 1047–1055, Oct. 2011, doi: 10.1111/j.1440-1843.2011.02019.x.
- G. J. Criner et al., “Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians,” Chronic Obstr. Pulm. Dis. Miami Fla, vol. 9, no. 3, pp. 454–476, Jul. 2022, doi: 10.15326/jcopdf.2022.0296.
- K. Szalontai et al., “Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving theWay to Lung Cancer,” J. Clin. Med., vol. 10, no. 13, p. 2889, Jun. 2021, doi: 10.3390/jcm10132889.
- T. Goldkorn, S. Filosto, and S. Chung, “Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor,” Antioxid. Redox Signal., vol. 21, no. 15, pp. 2149–2174, Nov. 2014, doi: 10.1089/ars.2013.5469.
- V. A. Kiri, J. Soriano, G. Visick, and L. Fabbri, “Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database,” Prim. Care Respir. J. J. Gen. Pract. Airw. Group, vol. 19, no. 1, pp. 57–61, Mar. 2010, doi: 10.4104/pcrj.2009.00048.
- D. J. Magliano, E. J. Boyko, and IDF Diabetes Atlas 10th edition scientific committee, IDF DIABETES ATLAS, 10th ed. in IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2021. Accessed: Jan. 20, 2025. [Online]. Available: http://www.ncbi.nlm.nih.gov/booksNBK581934/
- V. Durlach et al., “Smoking and diabetes interplay: A comprehensive review and joint statement,” Diabetes Metab., vol. 48, no. 6, p. 101370, Nov. 2022, doi: 10.1016/j.diabet.2022.101370.
- G. J. Molla et al., “Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran,” Can. J. Diabetes, vol. 44, no. 3, pp. 246–252, Apr. 2020, doi: 10.1016/j.jcjd.2019.07.002.
- I. Berlin, V. Durlach, D. Thomas, B. Verges, A.-L. Le Faou, and Working Group on Smoking and Diabetes, “Tobacco smoking and diabetes. A comparative survey among diabetologists and smoking cessation specialists,” Prim. Care Diabetes, vol. 18, no. 2, pp. 241–245, Apr. 2024, doi: 10.1016/j.pcd.2024.01.009.
- C. P. Wen, T. Y. D. Cheng, S. P. Tsai, H. L. Hsu, H. T. Chan, and C. C. Hsu, “Exploring the relationships between diabetes and smoking: with the development of glucose equivalent concept for diabetes management,” Diabetes Res. Clin. Pract., vol. 73, no. 1, pp. 70–76, Jul. 2006, doi: 10.1016/j.diabres.2005.12.005.
- T. E. Dorner, H. Brath, and A. Kautzky-Willer, “Sexspecific trends in smoking prevalence over seven years in different Austrian populations: results of a time-series cross-sectional analysis,” BMJ Open, vol. 10, no. 9, p. e035235, Sep. 2020, doi: 10.1136/bmjopen-2019-035235.
- P. M. Nilsson, S. Gudbjornsdottir, B. Eliasson, J. Cederholm, and Steering Committee of the Swedish National Diabetes Register, “Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes--data from the National Diabetes Register in Sweden,” Diabetes Metab., vol. 30, no. 3, pp. 261–268, Jun. 2004, doi: 10.1016/s1262-3636(07)70117-9.
- S. G. Wannamethee, A. G. Shaper, I. J. Perry, and British Regional Heart Study, “Smoking as amodifiable risk factor for type 2 diabetes in middle-aged men,” Diabetes Care, vol. 24, no. 9, pp. 1590–1595, Sep. 2001, doi: 10.2337/diacare.24.9.1590.
- F. Moayeri, Y.-S. A. Hsueh, D. Dunt, and P. Clarke, “Smoking Cessation and Quality of Life: Insights From Analysis of Longitudinal Australian Data, an Application for Economic Evaluations,” Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res., vol. 24, no. 5, pp. 724–732, May 2021, doi: 10.1016/j.jval.2020.11.022.
- G. Taylor, A. McNeill, A. Girling, A. Farley, N. Lindson-Hawley, and P. Aveyard, “Change in mental health after smoking cessation: systematic review and meta-analysis,” BMJ, vol. 348, p. g1151, Feb. 2014, doi: 10.1136/bmj.g1151.
- G. M. Taylor et al., “Smoking cessation for improving mental health,” Cochrane Database Syst. Rev., vol. 3, no. 3, p. CD013522, Mar. 2021, doi: 10.1002/14651858. CD013522.pub2.
- M. E. Piper, S. Kenford, M. C. Fiore, and T. B. Baker, “Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt,” Ann. Behav. Med. Publ. Soc. Behav. Med., vol. 43, no. 2, pp. 262–270, Apr. 2012, doi: 10.1007/s12160-011-9329-2.
- J. Tian, A. J. Venn, L. Blizzard, G. C. Patton, T. Dwyer, and S. L. Gall, “Smoking status and health-related quality of life: a longitudinal study in young adults,” Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil., vol. 25, no. 3, pp. 669–685, Mar. 2016, doi: 10.1007/s11136-015-1112-6.
- E. L. Bloom, H. Minami, R. A. Brown, D. R. Strong, D. Riebe, and A. M. Abrantes, “Quality of life after quitting smoking and initiating aerobic exercise,” Psychol. Health Med., vol. 22, no. 9, pp. 1127–1135, Oct. 2017, doi: 10.1080/13548506.2017.1282159.
- M. C. Miguez et al., “Health-related quality of life among smoking relapsers,” Psicothema, vol. 30, no. 1, pp. 27–32, Feb. 2018, doi: 10.7334/psicothema2017.61.
- G. Papadopoulos, C. I. Vardavas, M. Limperi, A. Linardis, G. Georgoudis, and P. Behrakis, “Smoking cessation can improve quality of life among COPD patients: validation of the clinical COPD questionnaire into Greek,” BMC Pulm. Med., vol. 11, p. 13, Feb. 2011, doi: 10.1186/1471-2466-11-13.
- V. Fazekas-Pongor et al., “Health-related quality of life of COPD patients aged over 40 years,” Physiol. Int., Jun. 2021, doi: 10.1556/2060.2021.00017.
- E. A. Flott, “Smoking Cessation Strategies for Patients with COPD,” Home Healthc. Now, vol. 33, no. 7, pp. 375–379, 2015, doi: 10.1097/NHH.0000000000000263.